• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: THERAKOS, INC/MALLINCKRODT PHARMACEUTICAL CELLEX SYSTEM; SYSTEMS, PHOTOPHERESIS, EXTRACORPOREAL

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

THERAKOS, INC/MALLINCKRODT PHARMACEUTICAL CELLEX SYSTEM; SYSTEMS, PHOTOPHERESIS, EXTRACORPOREAL Back to Search Results
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Dyspnea (1816); Embolism (1829); Thrombosis (2100)
Event Date 11/14/2019
Event Type  Injury  
Event Description
Pulmonary emboli (pe) and a deep vein thrombosis (dvt) was diagnosed in a patient receiving extracorporeal photopheresis (ecp).Treatment via the callex system for bronchiolitis obliterans syndrome (bos).The patient went to an outlying emergency department with complaints of shortness of breath and cough that started one hour prior to arrival.No chest pain.+tachypneas.Ct scan with contrast suggestion of a right middle lobe pulmonary embolism.Groundglass infiltrates lung bases right side greater than left.Patient was initially treated with lovenox and methylprednisolone and transferred to bjc.Lovenox was changed to heparin drip.(b)(6) 2019 lower extremity ultrasound showed acute deep vein thrombosis in the right posterior tibial and peroneal veins.No evidence of dvt in the left leg.Ct with contrast repeated (b)(6) 2019 showed pulmonary embolism involving the loar, segmental, and subsegmental branches of the right main pulmonary artery.No evidence of right heart strain.Groundglass opecities within the lung bases, right greater than the left, favored to represent an infectious inflammatory etiology versus scarring in the setting of bilateral lung transplantation.The patient had received 15 ecp treatments prior to the pe / dvt event.The pe/dvt event took place eight days after the last ecp treatment.The event was not related to the catheter used for the purpose of performing ecp.The physician felt the event was possibly related to the research.This event is being reported in light of the fda safety alert sent february 2018.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
CELLEX SYSTEM
Type of Device
SYSTEMS, PHOTOPHERESIS, EXTRACORPOREAL
Manufacturer (Section D)
THERAKOS, INC/MALLINCKRODT PHARMACEUTICAL
bedminster NJ
MDR Report Key9774680
MDR Text Key181810355
Report NumberMW5093400
Device Sequence Number1
Product Code LNR
Combination Product (y/n)N
Reporter Country CodeUS
Number of Events Reported1
Summary Report (Y/N)N
Report Source Voluntary
Reporter Occupation Nurse
Type of Report Initial
Report Date 02/25/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received Not provided
Initial Date FDA Received02/28/2020
Was Device Evaluated by Manufacturer? No Information
Type of Device Usage N
Patient Sequence Number1
Patient Outcome(s) Hospitalization;
Patient Age68 YR
Patient Weight92
-
-